BCR-ABL1
EstablishedBCR-ABL1 transcript monitoring (International Scale) is the standard for tracking CML treatment response and TKI discontinuation eligibility.
This fusion gene, created by a specific chromosome rearrangement, causes CML. Tracking its level in the blood over time is how doctors monitor treatment response, and if the level gets low enough and stays there for long enough, many patients can actually try stopping their medication altogether — something not possible for most of CML's treatment history.
BCR-ABL1 is a fusion gene created by the Philadelphia chromosome translocation, producing a constitutively active tyrosine kinase that defines chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia.
BCR-ABL1 transcript levels, measured on the International Scale (IS), are the standard method for monitoring treatment response to tyrosine kinase inhibitors (TKIs) in CML, with defined molecular response milestones guiding treatment decisions throughout therapy.
Measured via quantitative RT-PCR, standardized to the International Scale; major molecular response (MMR) is defined as BCR-ABL1 ≤0.1% IS, and deep molecular response (DMR, ≤0.01% IS or better) is a prerequisite for attempting treatment-free remission (TKI discontinuation).
Achieving and sustaining a deep molecular response for at least 2 years allows selected CML patients to attempt stopping TKI therapy altogether under close molecular monitoring — with roughly 50% successfully maintaining treatment-free remission in clinical trials and real-world studies, a genuinely significant quality-of-life development for a disease that once required lifelong medication.
Deep molecular response now allows roughly half of eligible CML patients to successfully stop lifelong TKI therapy (treatment-free remission).
- Haematologica. Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?
- PMC. (2020). Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice.